# Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

> **NCT05659290** · PHASE2 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib alternating with Bevacizumab plus Capecitabine
- **DRUG:** Bevacizumab plus Capecitabine

## Key facts

- **NCT ID:** NCT05659290
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659290, "Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05659290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*